Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2039846 | 0.91 | ESR2 (0.62) | PTPN5ESR2FFAR1AKR1B1GRIA2 | |
| Benzoic Acid SCHEMBL8919114 | 0.84 | ESR2 (0.58) | PTPN5ESR2FFAR1AKR1B1GRIA2 | |
| Trifluoroacetic Acid SCHEMBL3107487 | 0.84 | GRM5 (0.49) | PTPN5 | |
| SCHEMBL3644691 | 0.82 | TTR (0.47) | ESR2 | |
| Trifluoroacetic Acid SCHEMBL27851317 | 0.79 | KDM1A (0.48) | PTPN5FFAR1 | |
| P-Anisic Acid SCHEMBL2903597 | 0.77 | CA1 (0.56) | FFAR1AKR1B1 | |
| Trifluoroacetic Acid SCHEMBL6620503 | 0.77 | EGFR (0.58) | — | |
| Benzoic Acid SCHEMBL5166939 | 0.77 | ESR2 (0.49) | PTPN5ESR2FFAR1AKR1B1GRIA2 | |
| SCHEMBL6414144 | 0.76 | ESR2 (0.61) | PTPN5ESR2FFAR1AKR1B1GRIA2 | |
| SCHEMBL7837383 | 0.76 | ESR2 (0.51) | PTPN5ESR2FFAR1AKR1B1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | PTPN5 1516/4885ESR2 1971/4885FFAR1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.